In this issue:
Metagenomic identification of microbial signatures predicting pancreatic cancer
A faecal microbiota signature with high specificity for pancreatic cancer
Dynamic profiling of immune microenvironment during pancreatic cancer development
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab
Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumour microenvironment
Off-the-shelf prostate stem cell antigen– directed chimeric antigen receptor natural killer (NK) cell therapy to treat pancreatic cancer
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer
Neoadjuvant stereotactic body radiotherapy after upfront chemotherapy improves pathologic outcomes compared with chemotherapy alone
Preoperative oncologic therapy and the prolonged risk of venous thromboembolism
Please login below to download this issue (PDF)